“An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.” Newsletter2014 Advances in Basic Research There was a tremendous amount of new development

First Page		Document Content
Date: 2014-12-17 14:40:00 Ribbon symbolism Trastuzumab Ovarian cancer Cancer Targeted therapy PARP inhibitor PALB2 Bevacizumab Triple-negative breast cancer Medicine Oncology Breast cancer		“An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.” Newsletter2014 Advances in Basic Research There was a tremendous amount of new development Add to Reading List Source URL: www.sabcs.org Download Document from Source Website File Size: 646,99 KB Share Document on Facebook

	Dries 1 Annika Dries Human Biology 158G Final Project 6 December 2013 The PARP inhibitor: the promises and challenges of targeted breast cancer therapy DocID: 1uCeV - View Document
	Theranostics 2016, Vol. 6, IssueIvyspring DocID: 1q5FE - View Document
	The DNA damage response in tumorigenesis and cancer treatment Jiri Bartek and Jiri Lukas The cellular DNA damage response (DDR) machinery is intimately linked with cancer as damage to DNA causes cancer. The DDR provides DocID: 1p16I - View Document
	Final results of the phase I first-in-man trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carri DocID: 1lhcT - View Document
	Microsoft Word - BeiGene BGB 290 FPI Release_Final DocID: 1anIY - View Document